Effects of Thyrotropin Suppression on Bone Health in Menopausal Women with Total Thyroidectomy
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: This study examined the change in the trabecular bone score (TBS), areal bone mineral density (aBMD), and osteoporosis in postmenopausal women who underwent thyrotropin (TSH)-suppressive therapy for treating papillary thyroid cancer after a total thyroidectomy procedure. Methods: We evaluated 36 postmenopausal women who received a total thyroidectomy for papillary thyroid cancer and were undergoing TSH suppressive therapy with levothyroxine. Postmenopausal women (n=94) matched for age and body mass index were recruited as healthy controls. The aBMD and TBS of the lumbar spine were compared between dual energy X-ray absorptiometry (DXA) at baseline and at follow-up after an average of 4.92 years. Results: There was no significant difference in the rate of diagnoses of osteoporosis, osteopenia, or normal bone status between the 2 groups during the baseline DXA evaluation. However, the TBS was significantly lower whereas aBMD did not show significant difference at the time of baseline DXA measurement (1st DXA, 1.343±0.098 vs. 1.372±0.06317, P<0.001; 2nd DXA, 1.342±0.095 vs. 1.370±0.062, P<0.001). The TBS and aBMD did not differ significantly between the initial and follow-up DXA images in both groups of TSH suppressive patients and controls. Conclusions: The average value of TBS and aBMD did not significantly change during the follow-up period. The TSH suppressive therapy was revealed as not a significant factor for the progressive deterioration of bone status during long term follow-up.
Abstract
Background: This study examined the change in the trabecular bone score (TBS), areal bone mineral density (aBMD), and osteoporosis in postmenopausal women who underwent thyrotropin (TSH)-suppressive therapy for treating papillary thyroid cancer after a total thyroidectomy procedure. Methods: We evaluated 36 postmenopausal women who received a total thyroidectomy for papillary thyroid cancer and were undergoing TSH suppressive therapy with levothyroxine. Postmenopausal women (n=94) matched for age and body mass index were recruited as healthy controls. The aBMD and TBS of the lumbar spine were compared between dual energy X-ray absorptiometry (DXA) at baseline and at follow-up after an average of 4.92 years. Results: There was no significant difference in the rate of diagnoses of osteoporosis, osteopenia, or normal bone status between the 2 groups during the baseline DXA evaluation. However, the TBS was significantly lower whereas aBMD did not show significant difference at the time of baseline DXA measurement (1st DXA, 1.343±0.098 vs. 1.372±0.06317, P<0.001; 2nd DXA, 1.342±0.095 vs. 1.370±0.062, P<0.001). The TBS and aBMD did not differ significantly between the initial and follow-up DXA images in both groups of TSH suppressive patients and controls. Conclusions: The average value of TBS and aBMD did not significantly change during the follow-up period. The TSH suppressive therapy was revealed as not a significant factor for the progressive deterioration of bone status during long term follow-up.
참고문헌 (38)
- Abe E, "TSH is a negative regulator of skeletal remodeling", Cell, 115, pp.151~162 (2003)
- Sendak RA, "Newly reported roles of thyroid-stimulating hormone and follicle-stimulating hormone in bone remodelling", Int Orthop, 31, pp.753~757 (2007)
- Eriksen EF, "Trabecular bone remodeling and bone balance in hyperthyroidism", Bone, 6, pp.421~428 (1985)
- Mosekilde L, "Bone changes in hyperthyroidism: interrelationships between bone morphometry, thyroid function and calcium-phosphorus metabolism", Acta Endocrinol (Copenh), 85, pp.515~525 (1977)
- Biondi B, "Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer", Thyroid, 20, pp.135~146 (2010)
- Cady B, "The effect of thyroid hormone administration upon survival in patients with differentiated thyroid carcinoma", Surgery, 94, pp.978~983 (1983)
- Klein Hesselink EN, "Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study", J Clin Oncol, 31, pp.4046~4053 (2013)
- Flynn RW, "Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy", J Clin Endocrinol Metab, 95, pp.186~193 (2010)
- de Melo TG, "Low BMI and low TSH value as risk factors related to lower bone mineral density in postmenospausal women under levothyroxine therapy for differentiated thyroid carcinoma", Thyroid Res, 8, pp.7~ (2015)
- Bauer DC, "Risk for fracture in women with low serum levels of thyroid-stimulating hormone", Ann Intern Med, 134, pp.561~568 (2001)
- Ross DS, "Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine", Am J Med, 82, pp.1167~1170 (1987)
- Ross DS, "Hyperthyroidism, thyroid hormone therapy, and bone", Thyroid, 4, pp.319~326 (1994)
- Solomon BL, "Prevalence of fractures in postmenopausal women with thyroid disease", Thyroid, 3, pp.17~23 (1993)
- Grimnes G, "The relationship between serum TSH and bone mineral density in men and postmenopausal women : the Tromso study", Thyroid, 18, pp.1147~1155 (2008)
- Wang LY, "Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma", Thyroid, 25, pp.300~307 (2015)
- Pothuaud L, "Correlations between grey-level variations in 2D projection images (TBS) and 3D microarchitecture: applications in the study of human trabecular bone microarchitecture", Bone, 42, pp.775~787 (2008)
- Lee JE, "Comparisons of TBS and lumbar spine BMD in the associations with vertebral fractures according to the T-scores: a cross-sectional observation", Bone, 105, pp.269~275 (2017)
- Hwangbo Y, "High-normal free thyroxine levels are associated with low trabecular bone scores in euthyroid postmenopausal women", Osteoporos Int, 27, pp.457~462 (2016)
- Moon JH, "The effect of TSH suppression on vertebral trabecular bone scores in patients with differentiated thyroid carcinoma", J Clin Endocrinol Metab, 102, pp.78~85 (2017)
- Silva BC, "Trabecular bone score: perspectives of an imaging technology coming of age", Arq Bras Endocrinol Metabol, 58, pp.493~503 (2014)
- Cooper DS, "Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer", Thyroid, 19, pp.1167~1214 (2009)
- Biondi B, "Thyroid-hormone therapy and thyroid cancer: a reassessment", Nat Clin Pract Endocrinol Metab, 1, pp.32~40 (2005)
- Pacini F, "European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium", Eur J Endocrinol, 154, pp.787~803 (2006)
- Balme HW, "Metastatic carcinoma of the thyroid successfully treated with thyroxine", Lancet, 266, pp.812~813 (1954)
- McGriff NJ, "Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer", Ann Med, 34, pp.554~564 (2002)
- Sugitani I, "Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study", Surgery, 150, pp.1250~1257 (2011)
- Kung AW, "Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin", J Clin Endocrinol Metab, 81, pp.1232~1236 (1996)
- Heemstra KA, "The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma", Thyroid, 16, pp.583~591 (2006)
- Quan ML, "Bone mineral density in well-differentiated thyroid cancer patients treated with suppressive thyroxine: a systematic overview of the literature", J Surg Oncol, 79, pp.62~69 (2002)
- 이미영, "Bone mineral density and bone turnover markers in patients on long-term suppressive levothyroxine therapy for differentiated thyroid cancer", Annals of Surgical Treatment and Research, 86(2), pp.55~60 (2014), 대한외과학회
- Franklyn JA, "Long-term thyroxine treatment and bone mineral density", Lancet, 340, pp.9~13 (1992)
- 김채원, "Change of Bone Mineral Density and Biochemical Markers of Bone Turnover in Patients on Suppressive Levothyroxine Therapy for Differentiated Thyroid Carcinoma", 대한골대사학회지, 22(3), pp.135~141 (2015), 대한골대사학회[DOI]
- WHO Study Group, "Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group", World Health Organ Tech Rep Ser, 843, pp.1~129 (1994)
- Leslie WD, "Lumbar spine texture enhances 10-year fracture probability assessment", Osteoporos Int, 25, pp.2271~2277 (2014)
- Bousson V, "Trabecular bone score (TBS): available knowledge, clinical relevance, and future prospects", Osteoporos Int, 23, pp.1489~1501 (2012)
- Sampath TK, "Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats", J Bone Miner Res, 22, pp.849~859 (2007)
- Kim HY, "Role and mechanisms of actions of thyroid hormone on the skeletal development", Bone Res, 1, pp.146~161 (2013)
- Kim MK, "The effects of thyrotropin-suppressing therapy on bone metabolism in patients with well-differentiated thyroid carcinoma", Bone, 71, pp.101~105 (2015)